ArticleBMC biotechnology2026
PLGA nanofibers carrying rhFGF1 for the effective treatment of skin wounds in diabetic mice.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diabetic foot ulcers are among the most common complications of diabetes and can lead to delayed wound healing. Fibroblast growth factor (FGF1) is a classic drug for the treatment of skin wounds but has the disadvantages of a short half-life and instability. Poly (lactic-co-glycolic acid) (PLGA) nanofibers are sustained-release biomaterials that have potential for use as therapeutic delivery systems. However, the therapeutic effect of PLGA loaded with recombinant human FGF1 (rhFGF1) on diabetic wound healing is unknown. Therefore, this study aimed to explore the therapeutic effects of PLGA-rhFGF1 in type 2 diabetic (T2D) wound mice. We found that PLGA offers good sustained release, which enhances the stability and bioactivity of rhFGF1. PLGA-rhFGF1 promoted wound closure, re-epithelialization and the expression of keratin 10 and keratin 14 in T2D mice on day 14. PLGA-rhFGF1 significantly decreased the levels of TNF-α and IL-6 in serum and skin tissues as well as the level of IL-1β in skin tissues. Moreover, PLGA-rhFGF1 decreased the mRNA levels of CXCL1, MCP1 and MIP2, and the fluorescence intensity of F4/80 and Ly6G in T2D wound mice and increased the collagen content and the protein expression of collagen I in the dermis of T2D wounds. PLGA-rhFGF1 also increased blood flow; the mRNA levels of the angiogenesis-related factors VEGF, Ang-1 and eNOS and the fluorescence intensity of CD31 in T2D wound mice. These data indicate that PLGA releases rhFGF1 slowly and promotes skin wound healing in T2D mice. The mechanisms through which PLGA-rhFGF1 produces these effects involve decreased inflammation and the promotion of granulation, re-epithelialization and angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.